Alkem Laboratories
Alkem Laboratories Limited is an Indian pharmaceutical company engaged in the development, manufacturing, and sale of branded and generic pharmaceuticals. The company operates across domestic and international formulation business segments alongside active pharmaceutical ingredient (API) production. Its core therapeutic categories include anti-infectives, gastroenterology, pain management, central nervous system, and anti-diabetic treatments. Primary revenue drivers are retail pharmaceutical sales in India alongside generic drug exports to the United States and emerging markets. Alkem Laboratories holds a market-leading position in India's acute pharmaceutical market segment. The company is headquartered in Mumbai, India, and its shares trade on the National Stock Exchange of India and BSE Limited.
11 of the funds FundTelligence covers report a position in Alkem Laboratories.
- Legal name
- Alkem Laboratories Ltd.
- Sector
- Health Care
- Country
- India
- Funds holding it
- 11
Funds holding Alkem Laboratories
- Storebrand Emerging Markets — Storebrand · 0.04 % (full portfolio disclosed, October 2026)
- Mercer Passive Emerging Markets Equity Fund — Mercer · 0.03 % (full portfolio disclosed, December 2025)
- Danske Invest Global Emerging Markets Index Restricted — Danske Invest · 0.02 % (full portfolio disclosed, July 2026)
- DNB Emerging Markets Index — DNB · 0.02 % (full portfolio disclosed, September 2026)
- Storebrand Indeks Nye Markeder — Storebrand · 0.02 % (full portfolio disclosed, October 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.02 % (full portfolio disclosed, October 2026)
- KLP AksjeFremvoksende Markeder Indeks — KLP · 0.02 % (full portfolio disclosed, June 2026)
- Handelsbanken Global Index Criteria — Handelsbanken · 0.01 % (full portfolio disclosed, September 2026)
Showing the 8 largest of 11 funds holding it.